Polymorphisms as markers of sunitinib efficacy and toxicity in first-line treatment of renal clear cell carcinoma: Final results of a multicentric prospective study by the Spanish Oncology Genitourinary Group.
J. Garcia-Donas
Honoraria - GlaxoSmithKline; Novartis; Pfizer
Research Funding - Novartis; Pfizer
E. Esteban
No relevant relationships to disclose
L. J. Leandro-García
Research Funding - Pfizer (B)
D. E. Castellano
No relevant relationships to disclose
A. Gonzalez del Alba
No relevant relationships to disclose
M. A. Climent
No relevant relationships to disclose
J. A. Arranz
No relevant relationships to disclose
E. Gallardo
No relevant relationships to disclose
J. Puente
No relevant relationships to disclose
J. Bellmunt
Consultant or Advisory Role - Pfizer
B. Mellado
No relevant relationships to disclose
E. Martínez
No relevant relationships to disclose
F. Moreno
No relevant relationships to disclose
A. Font
No relevant relationships to disclose
M. Robledo
No relevant relationships to disclose
C. Rodriguez de Antona
Research Funding - Pfizer